Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab in metastatic castration-resistant prostate cancer with IDC-P component
ChiCTR2400085267Phase 2Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jun 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in prostate cancer (PCa), sponsored by West China Hospital of Sichuan University. Primary endpoints: PSA progression-free survival, Radiographic progression-free survival and 1 more. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
tislelizumab
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on ChiCTR2400085267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400085267.